4.8 Article

Single-dose CRISPR-Cas9 therapy extends lifespan of mice with Hutchinson-Gilford progeria syndrome

Journal

NATURE MEDICINE
Volume 25, Issue 3, Pages 419-+

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/s41591-019-0343-4

Keywords

-

Funding

  1. Catharina Foundation
  2. Muscular Dystrophy Association
  3. NIH-NCI CCSG [P30 014195]
  4. Helmsley Trust
  5. Progeria Research Foundation
  6. Universidad Catolica San Antonio de Murcia (UCAM)
  7. Fundacion Dr. Pedro Guillen
  8. G. Harold and Leila Y. Mathers Charitable Foundation
  9. Glenn Foundation
  10. Moxie Foundation

Ask authors/readers for more resources

Hutchinson-Gilford progeria syndrome (HGPS) is a rare lethal genetic disorder characterized by symptoms reminiscent of accelerated aging. The major underlying genetic cause is a substitution mutation in the gene coding for lamin A, causing the production of a toxic isoform called progerin. Here we show that reduction of lamin A/progerin by a single-dose systemic administration of adeno-associated virus-delivered CRISPR-Cas9 components suppresses HGPS in a mouse model.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available